Although tyrosine kinase inhibitors (TKIs) are first-line therapies for CML, BCR-ABL-mediated drug resistance limits their clinical efficacy and patient prognosis. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.